ℹ️
🇬🇧
Search
Search for publications relevant for "relapsing multiple-sclerosis"
relapsing multiple-sclerosis
Publication
Class
Person
Publication
Programmes
publication
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
2009 |
First Faculty of Medicine
publication
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis : CLARIFY-MS study 6-month interim analysis
2022 |
First Faculty of Medicine, Faculty of Medicine in Hradec Králové
publication
A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting
2006 |
First Faculty of Medicine
publication
A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting
2006 |
Faculty of Physical Education and Sport
publication
A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis
2006 |
First Faculty of Medicine
publication
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program
2021 |
First Faculty of Medicine
publication
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
2007 |
First Faculty of Medicine
publication
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
2007 |
Faculty of Physical Education and Sport
publication
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
2010 |
Second Faculty of Medicine
publication
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
2015 |
First Faculty of Medicine
publication
The effects of natalizumab on a test of cognitive function in patients with relapsing multiple sclerosis (MS)
Publication without faculty affiliation
publication
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
2012 |
Second Faculty of Medicine
publication
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study
2022 |
Faculty of Medicine in Hradec Králové
publication
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial
2019 |
First Faculty of Medicine
publication
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
2019 |
First Faculty of Medicine
publication
Comparison of switch to fingolimod and continued treatment with glatiramer acetate or interferon Beta in patients with relapsing multiple sclerosis: Follow-up analysis of the EPOC clinical trial
2015 |
Publication without faculty affiliation
publication
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
2021 |
First Faculty of Medicine
publication
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
2012 |
First Faculty of Medicine
publication
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
2023 |
First Faculty of Medicine
publication
Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
2017 |
First Faculty of Medicine, Second Faculty of Medicine
publication
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
2018 |
First Faculty of Medicine
publication
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
2022 |
First Faculty of Medicine, Faculty of Medicine in Hradec Králové
publication
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
2022 |
First Faculty of Medicine
publication
Clinical results from AFFIRM: a randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of Natalizumab in patients with relapsing multiple sclerosis
Publication without faculty affiliation
publication
The incidence and significance of anti-natalizumab antibodies - Results from AFFIRM and SENTINEL
2007 |
Second Faculty of Medicine
publication
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
2023 |
First Faculty of Medicine
publication
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS
2016 |
First Faculty of Medicine
publication
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
2023 |
First Faculty of Medicine
publication
Treatment of multiple sclerosis with oral cladribine: results of clinical trials
2017 |
First Faculty of Medicine
publication
Report of University Hospital Hradec Králové to the clinical trial protocol No: WA21092
Publication without faculty affiliation